NHLBI Progenitor Cell Translational Consortium (U01)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement requests applications to participate in the NHLBI Progenitor Cell Translational Consortium (PCTC). The goal of the Consortium is to translate advances in progenitor cell biology towards application to heart, lung, and blood diseases. The initiative will focus on the use of progenitor cell-based disease models to understand disease mechanisms, the development of novel therapies, and the application of cell-based therapies for the treatment of diseases.

The goal of this FOA is to develop a highly interactive and synergistic Consortium of investigators who will share ideas, data and resources to advance translation of progenitor cell biology. Thus, in addition to interactions within a Research Hub, extensive collaboration among Research Hubs is expected and may include collaborations between investigators at multiple institutions. The Consortium will consist of Research Hubs funded through this FOA, and an Administrative Coordinating Center (ACC) that will be responsible for enabling collaboration across the consortium through logistical support and a variety of tasks. The ACC will also administer funds to support pilot studies, ancillary and collaborative research studies, and skills development activities.  The ACC is funded through a separate FOA, RFA-HL-16-022. Applicants to this Consortium FOA are strongly encouraged to read the ACC FOA.   


  • Letter of Intent Due Date(s): January 8, 2016
  • Application Due Date(s): February 8, 2016, by 5:00 PM local time of applicant organization.

​RFA-HL-16-021 Expiration Date February 9, 2016

Agency Website



Amount Description

Application budgets are limited to $600,000 Direct Costs per year in Fiscal Years 2016 and 2017 and $800,000 Direct Costs per year in Fiscal Years 2018 through 2022.

Direct costs (all years) may not exceed $5,200,000. The maximum project period for an application submitted in response to this funding opportunity is up to seven years.

Funding Type





Engineering and Physical Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

February 8, 2016